Skye Bioscience Highlights Novel Synthetic Cannabinoid-based Library Capable of Modulating the Endocannabinoid System to Treat Ocular Diseases at ARVO 2024 Annual Meeting
Skye Bioscience to Present Two Posters at Association for Research in Vision and Ophthalmology (ARVO) 2024 Annual Meeting
Skye Bioscience to Present at Upcoming Investment Conferences
Skye Bioscience, Inc. (NASDAQ: SKYE) is now covered by analysts at Oppenheimer Holdings Inc.. They set an "outperform" rating and a $25.00 price target on the stock.
Skye Bioscience, Inc. (OTCMKTS: SKYE) is now covered by analysts at Oppenheimer Holdings Inc.. They set an "outperform" rating and a $25.00 price target on the stock.